Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease

NCT06989359 is registered in ClinicalTrials.gov with ADARx Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06989359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06989359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
Lead sponsor
ADARx Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 28, 2025
Completion date
June 30, 2029
Enrollment
45 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

c3g, complement-mediated kidney disease, ic-mpgn, iga nephropathy (igan), igan